论文部分内容阅读
近期,生物医药板块可谓是利好不断,不仅有“超级细菌”和“蜱虫事件”的事件性刺激,还有国家战略性新兴产业政策的重点扶持,投资机会凸显。
Recently, the biomedical segment is enjoying good momentum. There are not only incidental stimuli such as superbugs and ticks, but also key support from the state’s strategic emerging industries and investment opportunities.